Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESH MM 2018 | Updated CASTOR analysis: daratumumab plus Vd for R/R myeloma

Maria-Victoria Mateos • 5 Oct 2018
ESH MM 2018
Multiple Myeloma Antibodies Bortezomib Daratumumab Dexamethasone
CASTOR

Maria-Victoria Mateos, MD, PhD, of the University of Salamanca, Salamanca, Spain, discusses the updated analysis of the CASTOR trial (NCT02136134) with us at the European School of Haematology (ESH) International Conference on Multiple Myeloma 2018, held in Mandelieu, France. This trial investigated daratumumab plus bortezomib/dexamethasone for relapsed/refractory multiple myeloma, and this follow-up showed excellent response rates and survival benefit, in addition to indicating the group that will receive the maximum benefit from this regimen.

More from Maria-Victoria Mateos

2:44
Dual-targeting bispecific antibody alnuctamab in R/R multiple myeloma
Maria-Victoria Mateos • 9 Dec 2023
2:26
Preliminary results of GEM2017FIT: comparing induction therapies in fit elderly patients with MM
Maria-Victoria Mateos • 9 Dec 2023
4:21
CAR-T in multiple myeloma: progress in the space and what can be done to improve patient outcomes
Maria-Victoria Mateos • 17 Feb 2024
Latest advances in T-cell engaging therapies for multiple myeloma
Adam Cohen et al. • 15 Apr 2023

Related Videos

Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals